// App-Quantinova.ai

: Nivolumab Plus ICE As First Salvage Therapy in High-Risk Relapsed/Refractory Hodgkin Lymphoma

Researchers

Presenter

  • Matthew Mei

Principal Investigators

  • Joycelynne Palmer

  • Ni-Chun Tsai

  • Hun Ju Lee

  • Iris Isufi

  • Leslie L. Popplewell

  • Lynne Smith

  • Lacolle Peters

  • Lara Rodriguez

  • James Godfrey

  • John H. Baird

  • Joo Y. Song

  • Steven T. Rosen

  • Larry W. Kwak

  • Stephen J Forman

  • Alex F. Herrera

Medical Centers

  • City of Hope Comprehensive Cancer Center, Duarte, CA

  • Department of Computational and Quantitative Medicine, Beckman Research Institute, City of Hope, Duarte, CA

  • Department of Computational and Quantitative Medicine-BRI, City of Hope National Medical Center, Duarte, CA

  • Department of Hematology/HCT, City of Hope, Beckman Research Institute, Duarte, CA

  • Hematology, Yale University School of Medicine, New Haven, CT

  • Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX

  • Department of Hematology/Hematopoietic Cell Transplantation, City of Hope National Medical Center, Duarte, CA

  • City of Hope, Duarte, CA

  • City of Hope National Medical Center, Duarte, CA

  • Toni Stephenson Lymphoma Center, Department of Hematology and Hematopoietic Stem Cell Transplantation, Beckman Research Institute of the City of Hope, City of Hope National Medical Center, Duarte, CA

  • Department of Pathology, City of Hope National Medical Center, Duarte, CA

Locations

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Hodgkin's Lymphoma

Biomarkers

  • N/A

Drug/Treatment

  • brentuximab vedotin

  • Adcetris

  • Nivolumab

Outcome

  • N/A

Study Design

  • Multicenteric

  • Prospective

  • Cohort

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved